| 臺大學術典藏 |
2022-05-10T08:09:42Z |
Efficacy of second-line regimens for Helicobacter pylori eradication treatment: A systemic review and network meta-analysis
|
Chang Y.-L.; Tung Y.-C.; YU-KANG TU; Yeh H.-Z.; Yang J.-C.; Hsu P.-I.; Kim S.-E.; Wu M.-F.; Liou W.-S.; Shiu S.-I. |
| 臺大學術典藏 |
2022-03-04T08:22:44Z |
Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey)
|
Chuah Y.-Y.; Wu D.-C.; Chuah S.-K.; JYH-CHIN YANG; Lee T.-H.; Yeh H.-Z.; Chen C.-L.; Liu Y.-H.; Hsu P.-I. |
| 臺大學術典藏 |
2022-03-04T08:22:43Z |
Efficacy of second-line regimens for Helicobacter pylori eradication treatment: A systemic review and network meta-analysis
|
Chang Y.-L.; Tung Y.-C.; Tu Y.-K.; Yeh H.-Z.; JYH-CHIN YANG; Hsu P.-I.; Kim S.-E.; Wu M.-F.; Liou W.-S.; Shiu S.-I. |
| 臺大學術典藏 |
2022-01-24T09:32:03Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
CHUN-JEN LIU; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:38Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
CHUN-JEN LIU; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2021-09-04T06:19:01Z |
Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C
|
Yang S.-S.; Fu L.-S.; Chang C.-S.; Yeh H.-Z.; Chen G.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:25Z |
IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients
|
Chuang J.Y.; Yang S.S.; Lu Y.T.; Hsieh Y.Y.; Chen C.Y.; Chang S.C.; Chang C.S.; Yeh H.Z.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-01T02:02:15Z |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma
|
Chen L.-T.; Lin J.-T.; Tai J.J.; Chen G.-H.; Yeh H.-Z.; Yang S.-S.; Wang H.-P.; Kuo S.-H.; Sheu B.-S.; Jan C.-M.; Wang W.-M.; Wang T.-E.; Wu C.-W.; Chen C.-L.; Su I.-J.; Whang-Peng J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-07-03T03:34:53Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:34:06Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-05-27T02:50:07Z |
Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey)
|
Chuah Y.-Y.; Wu D.-C.; Chuah S.-K.; JYH-CHIN YANG; Lee T.-H.; Yeh H.-Z.; Chen C.-L.; Liu Y.-H.; Hsu P.-I. |
| 臺大學術典藏 |
2021-05-27T02:50:06Z |
Efficacy of second-line regimens for Helicobacter pylori eradication treatment: A systemic review and network meta-analysis
|
Chang Y.-L.; Tung Y.-C.; Tu Y.-K.; Yeh H.-Z.; JYH-CHIN YANG; Hsu P.-I.; Kim S.-E.; Wu M.-F.; Liou W.-S.; Shiu S.-I. |
| 臺大學術典藏 |
2021-05-06T08:30:57Z |
Efficacy of second-line regimens for Helicobacter pylori eradication treatment: A systemic review and network meta-analysis
|
Chang Y.-L.;Tung Y.-C.;Yu-Kang Tu;Yeh H.-Z.;Yang J.-C.;Hsu P.-I.;Kim S.-E.;Wu M.-F.;Liou W.-S.;Shiu S.-I.; Chang Y.-L.; Tung Y.-C.; YU-KANG TU; Yeh H.-Z.; Yang J.-C.; Hsu P.-I.; Kim S.-E.; Wu M.-F.; Liou W.-S.; Shiu S.-I. |
| 臺大學術典藏 |
2021-02-23T08:26:42Z |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma
|
Chen L.-T.;Lin J.-T.;Tai J.J.;Chen G.-H.;Yeh H.-Z.;Yang S.-S.;Wang H.-P.;Sung-Hsin Kuo;Sheu B.-S.;Jan C.-M.;Wang W.-M.;Wang T.-E.;Wu C.-W.;Chen C.-L.;Su I.-J.;Whang-Peng J.;Cheng A.-L.; Chen L.-T.; Lin J.-T.; Tai J.J.; Chen G.-H.; Yeh H.-Z.; Yang S.-S.; Wang H.-P.; SUNG-HSIN KUO; Sheu B.-S.; Jan C.-M.; Wang W.-M.; Wang T.-E.; Wu C.-W.; Chen C.-L.; Su I.-J.; Whang-Peng J.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-15T03:47:46Z |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma
|
Chen L.-T.; Lin J.-T.; Tai J.J.; Chen G.-H.; Yeh H.-Z.; Yang S.-S.; HSIU-PO WANG; Kuo S.-H.; Sheu B.-S.; Jan C.-M.; Wang W.-M.; Wang T.-E.; Wu C.-W.; Chen C.-L.; Su I.-J.; Whang-Peng J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-12-30T02:43:25Z |
IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients
|
Hsieh Y.Y.; Lu Y.T.; Chuang J.Y.; Yang S.S.; Chen C.Y.; SHAN-CHWEN CHANG; Chang C.S.; Yeh H.Z.; Kao J.H. |
| 臺大學術典藏 |
2020-11-19T03:19:55Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-11-19T03:19:23Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J.; Liu C.-J.; Chang J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B. |
| 臺大學術典藏 |
2020-02-19T09:33:57Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-02-19T09:33:45Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Chen P.-J.; Chang S.S.-C.; Lai K.-L.; Peng C.-Y.; Hu R.-H.; Yu M.-C.; Yang M.-D.; Yang S.-S.; MING-CHIH HO; Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z. |
| 國立成功大學 |
2020 |
Distinct Physiological Characteristics of Isolated Laryngopharyngeal Reflux Symptoms
|
Lien, H.-C.;Wang, C.-C.;Kao, J.Y.;Yeh, H.-Z.;Hsu, J.-Y.;Lee, S.-W.;Chuang, Chuang C.-Y.;Tsou, Y.-A.;Wang, J.-D.;Vaezi, M.F.;Chang, Chang C.-S. |
| 臺大學術典藏 |
2018-09-10T07:39:50Z |
IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients
|
Chuang, J.Y.; Yang, S.S.; Lu, Y.T.; Hsieh, Y.Y.; Chen, C.Y.; Chang, S.C.; Chang, C.S.; Yeh, H.Z.; Kao, J.H.; JIA-HORNG KAO; Chuang, J.Y.; Yang, S.S.; Lu, Y.T.; Hsieh, Y.Y.; Chen, C.Y.; Chang, S.C.; Chang, C.S.; Yeh, H.Z.; Kao, J.H. |
| 臺大學術典藏 |
2018-09-10T06:00:48Z |
Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C
|
Yang, S.-S.;Fu, L.-S.;Chang, C.-S.;Yeh, H.-Z.;Chen, G.-H.;Kao, J.-H.; JIA-HORNG KAO |
| 國立成功大學 |
2017 |
Alcohol and tea consumption are associated with asymptomatic erosive esophagitis in Taiwanese men
|
Chang, Chang C.-H.;Wu, C.-P.;Wang, J.-D.;Lee, S.-W.;Chang, Chang C.-S.;Yeh, H.-Z.;Ko, C.-W.;Lien, H.-C. |
| 中國醫藥大學 |
2009-04 |
Increasing Prevalence of Erosive Esophagitis Among Taiwanese Aged 40 Years and Above A Comparison Between Two Time Periods
|
(Lien, H.C.); Chang CS; (Yeh, H.Z.); 郭憲文(Hsien-Wen Kuo); (Chang, H.Y.); 鄭光甫(Kuang-Fu Cheng); 宋鴻樟(Fung-Chang Sung) |
